Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Allakos has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2022.
Allakos's investors include Samsara BioCapital, Vivo Capital, New Enterprise Associates, Redmile Group, TCG Crossover.
Allakos is headquartered in Redwood City, United States.
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Allakos is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allakos — Funding & Investors." VCBacked, September 19, 2022, https://www.vcbacked.co/company/allakos. Accessed August 16, 2026.
VCBacked. (2022). Allakos — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/allakos
{{cite web |title=Allakos — Funding & Investors |url=https://www.vcbacked.co/company/allakos |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated